MA38576A1 - Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières - Google Patents

Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières

Info

Publication number
MA38576A1
MA38576A1 MA38576A MA38576A MA38576A1 MA 38576 A1 MA38576 A1 MA 38576A1 MA 38576 A MA38576 A MA 38576A MA 38576 A MA38576 A MA 38576A MA 38576 A1 MA38576 A1 MA 38576A1
Authority
MA
Morocco
Prior art keywords
methods
colchicine
extended
same
release formulations
Prior art date
Application number
MA38576A
Other languages
English (en)
Other versions
MA38576B2 (fr
Inventor
Susanne Riel
Original Assignee
Murray And Poole Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Murray And Poole Entpr Ltd filed Critical Murray And Poole Entpr Ltd
Publication of MA38576A1 publication Critical patent/MA38576A1/fr
Publication of MA38576B2 publication Critical patent/MA38576B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention se rapporte à des compositions pharmaceutiques de colchicine à administrer une fois par jour par voie orale. Les formulations comprennent un composant à libération prolongée et un composant facultatif à libération immédiate, dont les compositions peuvent être ajustées de façon sélective, respectivement, pour libérer le principe actif selon un profil de libération prédéfini ou souhaité. La présente invention se rapporte également à des méthodes permettant de traiter ou d'empêcher une maladie cardiovasculaire et/ou une maladie inflammatoire chez des sujets mammaliens, lesdites méthodes comprenant l'administration des nouvelles formulations décrites ici.
MA38576A 2013-11-26 2014-04-16 Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières MA38576B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13194505 2013-11-26
PCT/IB2014/001201 WO2014170755A2 (fr) 2013-04-16 2014-04-16 Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières

Publications (2)

Publication Number Publication Date
MA38576A1 true MA38576A1 (fr) 2017-05-31
MA38576B2 MA38576B2 (fr) 2020-02-28

Family

ID=49683519

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38576A MA38576B2 (fr) 2013-11-26 2014-04-16 Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières

Country Status (19)

Country Link
US (7) US20160081936A1 (fr)
EP (1) EP2986280B1 (fr)
JP (1) JP6480420B2 (fr)
KR (1) KR102271048B1 (fr)
CN (1) CN105307643A (fr)
AU (4) AU2014255434B2 (fr)
BR (1) BR112015026418B1 (fr)
CA (2) CA2909370A1 (fr)
CL (1) CL2015003072A1 (fr)
EA (1) EA037375B1 (fr)
MA (1) MA38576B2 (fr)
MX (2) MX377426B (fr)
MY (2) MY198452A (fr)
PL (1) PL2986280T3 (fr)
PT (1) PT2986280T (fr)
SG (1) SG11201508571WA (fr)
SI (1) SI2986280T1 (fr)
WO (1) WO2014170755A2 (fr)
ZA (1) ZA201507723B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201503440UA (en) 2012-11-02 2015-06-29 Heart Care Western Australia Pty Ltd Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
HUE054663T2 (hu) * 2013-04-16 2021-09-28 Murray & Poole Entpr Ltd A kolicicin tartós kibocsátási készítményei és az annak alkalmazás módszerei
BR112015026418B1 (pt) 2013-04-16 2022-10-04 Murray And Poole Enterprises Limited Formulação de liberação prolongada de colchicina e uso da referida formulação de liberação prolongada de colchicina
WO2016166732A1 (fr) * 2015-04-17 2016-10-20 Murray And Poole Enterprises Limited Salicylate de colchicine et ses utilisations
US9907751B2 (en) 2016-03-10 2018-03-06 RxOMEG Therapeutics LLC Composition and method of use of colchicine oral liquid
PL3641726T3 (pl) * 2017-06-23 2026-02-23 Nordiccan A/S Woreczek z kannabinoidami
US10226423B1 (en) * 2017-12-20 2019-03-12 RxOMEG Therapeutics LLC Colchicine drug-to-drug interactions
EA202091736A1 (ru) 2018-02-02 2020-10-19 Марри Энд Пул Энтерпрайзес, Лтд. Применение колхицина для ингибирования роста опухоли и метастазов
AR119319A1 (es) * 2019-07-09 2021-12-09 Lilly Co Eli Procesos e intermediario para la preparación a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida y preparación de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida
CN110448527B (zh) * 2019-09-23 2021-11-26 杭州百诚医药科技股份有限公司 一种秋水仙碱口服溶液及其处方组成
GB201913827D0 (en) * 2019-09-25 2019-11-06 Cape Peninsula Univ Of Technology Sustained Release Formulation Containing Aspalathus linearis Extract
KR102112456B1 (ko) 2019-11-13 2020-05-19 주식회사 에이스바이오메드 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친 복합제제
US12514832B2 (en) 2019-11-15 2026-01-06 Institut De Cardiologie De Montreal Methods for using low-dose colchicine after myocardial infarction
CN111150702B (zh) * 2019-12-04 2021-06-22 复旦大学 一种凝胶药物缓释制剂及其制备方法与应用
WO2021145699A1 (fr) 2020-01-17 2021-07-22 한국생명공학연구원 Composition pour le traitement de maladies de la peau, comprenant de la colchicine
KR102150821B1 (ko) 2020-01-22 2020-09-03 주식회사 에이스바이오메드 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친 복합제제
KR20210095249A (ko) 2020-01-22 2021-08-02 주식회사 에이스바이오메드 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친 복합제제
KR102177781B1 (ko) 2020-04-27 2020-11-12 주식회사 에이스바이오메드 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친, 우르소데옥시콜산 및 비페닐디메틸디카르복실레이트의 복합제제
US20240075045A1 (en) * 2020-12-15 2024-03-07 Romeg Therapeutics Llc Methods and compositions for treating pericarditis
WO2022266065A1 (fr) * 2021-06-15 2022-12-22 Edwards Lifesciences Corporation Ensembles valve prothétique
CN113476603B (zh) * 2021-07-08 2022-05-20 中南大学 一种红细胞膜包裹的磁性纳米颗粒及其制备方法和应用
CN118717741A (zh) * 2024-01-15 2024-10-01 华中科技大学同济医学院附属协和医院 秋水仙碱在制备用于增加冠状动脉斑块纤维帽厚度药物中的应用
KR102870211B1 (ko) * 2024-06-11 2025-10-16 (주)알피바이오 지속성 제제 조성물
CN121265579A (zh) * 2025-12-11 2026-01-06 华中科技大学同济医学院附属协和医院 秋水仙碱在制备tbk1磷酸化促进剂中的应用
CN122230030A (zh) * 2026-05-20 2026-06-19 深圳湾实验室 化合物或其衍生物或其盐在防治病毒垂直传播中的应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
SE9003904D0 (sv) * 1990-12-07 1990-12-07 Astra Ab Method for the manufacture of a pharmaceutical dosage form
US5171217A (en) 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
US7820383B2 (en) 1997-03-10 2010-10-26 Interleukin Genetics, Inc. Method for diagnosing myocardial infarction
JP2000034224A (ja) * 1998-05-11 2000-02-02 Freunt Ind Co Ltd 徐放性錠剤、その添加剤組成物及びそれらの製造方法
US20020169145A1 (en) * 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
CZ20022140A3 (cs) * 1999-12-22 2002-11-13 Pharmacia Corporation Formulace inhibitoru cyklooxygenázy -2 s postupným uvolňováním
KR20040047747A (ko) 2001-03-13 2004-06-05 펜웨스트 파머슈티칼즈 컴파니 변시치료 제형
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US20030144203A1 (en) * 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
US20080039408A1 (en) 2004-12-06 2008-02-14 Ronald Freudenberger Use of Oxypurinol as an Inhibitor of Anti-Neoplastic Agent-Induced Cardiotoxicity
US20060171948A1 (en) 2005-02-02 2006-08-03 Weinstein Steven P Methods of using IL-1 antagonists to reduce C-reactive protein
US20060286108A1 (en) 2005-06-16 2006-12-21 Bell Katherine A Topical compositions for the treatment of chronic wounds
CN1748671A (zh) 2005-08-30 2006-03-22 孔庆忠 含抗有丝分裂药物的缓释注射剂
CN1939290A (zh) 2005-09-29 2007-04-04 陆宪光 秋水仙碱及它的衍生物的医学用途
US20090215687A1 (en) 2005-10-21 2009-08-27 Cornell Research Foundation, Inc. Compounds for Enhancing Hypoxia Inducible Factor Activity and Methods of Use
EP2023874A4 (fr) 2006-06-02 2009-07-08 Bioseek Inc Procédés d'identification d'agents et leur utilisation pour la prévention d'une resténose
PL2029134T3 (pl) * 2006-06-09 2011-12-30 Ucb Pharma Gmbh Stabilizowane kompozycje farmaceutyczne zawierające fezoterodynę
PT103884A (pt) * 2006-11-17 2008-05-19 Astrazeneca Ab Composições de libertação prolongada e métodos para a sua preparação
WO2008131192A2 (fr) 2007-04-18 2008-10-30 The Trustees Of Columbia University In The City Of New York Cholestérol cristallin et prévention de l'athérosclérose
US20090093548A1 (en) * 2007-10-05 2009-04-09 Mutual Pharmaceutical Company, Inc Colchine compositions and methods
CN101485637B (zh) * 2008-01-18 2011-03-30 普尔药物科技开发（深圳）有限公司 秋水仙碱骨架控释片或胶囊
CN101485638A (zh) * 2008-01-18 2009-07-22 普尔药物科技开发（深圳）有限公司 秋水仙碱双层渗透泵控释片及其制备方法
WO2009097450A1 (fr) 2008-01-30 2009-08-06 Dexcom. Inc. Système de capteur à marqueur cardiaque en continu
CN101536990A (zh) * 2008-03-18 2009-09-23 普尔药物科技开发（深圳）有限公司 秋水仙碱胃漂浮缓释片及其制备方法
WO2009151770A2 (fr) 2008-04-15 2009-12-17 Mutual Pharmaceutical Company, Inc. Formes de colchicine à l’état solide, procédés de fabrication et procédés d’utilisation associés
DE102008047910A1 (de) * 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
GB0819287D0 (en) 2008-10-22 2008-11-26 Univ Bradford Compounds
CN101732274A (zh) * 2008-11-19 2010-06-16 普尔药物科技开发（深圳）有限公司 秋水仙碱双层缓释片及其制备方法
US7820681B1 (en) 2009-01-14 2010-10-26 Mutual Pharmaceutical Company, Inc. Methods for concomitant administration of colchicine and a second active agent
US8945622B2 (en) 2009-03-09 2015-02-03 Council Of Scientific And Industrial Research Sustained release composition of therapeutic agent
US20110046228A1 (en) 2009-08-20 2011-02-24 Mutual Pharmaceutical Company, Inc. Methods for administration of colchicine with grapefruit juice
US20110046227A1 (en) 2009-08-21 2011-02-24 Mutual Pharmaceutical Company, Inc. Methods for concomitant administration of colchicine and a second active agent
CN102711739B (zh) 2009-11-13 2015-12-16 阿斯利康(瑞典)有限公司 双层片剂
EP2481411A1 (fr) * 2011-01-27 2012-08-01 Ratiopharm GmbH Formes galéniques orales pour libération modifiée comportant l'inhibiteur de JAK3 tasocitinib
AU2013245675B2 (en) 2012-04-13 2017-02-09 Cymabay Therapeutics, Inc. Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
SG11201503440UA (en) 2012-11-02 2015-06-29 Heart Care Western Australia Pty Ltd Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
BR112015026418B1 (pt) 2013-04-16 2022-10-04 Murray And Poole Enterprises Limited Formulação de liberação prolongada de colchicina e uso da referida formulação de liberação prolongada de colchicina
CN110148563A (zh) 2019-05-23 2019-08-20 武汉新芯集成电路制造有限公司 一种半导体器件及其制造方法

Also Published As

Publication number Publication date
SI2986280T1 (sl) 2021-08-31
BR112015026418A2 (pt) 2017-07-25
US10130585B2 (en) 2018-11-20
EA201501024A1 (ru) 2016-08-31
JP6480420B2 (ja) 2019-03-13
WO2014170755A3 (fr) 2015-02-19
US20150094323A1 (en) 2015-04-02
AU2020294268A1 (en) 2021-01-28
KR20150143725A (ko) 2015-12-23
CA2909370A1 (fr) 2014-10-23
MA38576B2 (fr) 2020-02-28
AU2014255434B2 (en) 2018-11-08
MY207496A (en) 2025-02-28
AU2024205185A1 (en) 2024-08-15
US10105319B2 (en) 2018-10-23
US10610488B2 (en) 2020-04-07
SG11201508571WA (en) 2015-11-27
US12691072B1 (en) 2026-07-28
PL2986280T3 (pl) 2021-10-25
CL2015003072A1 (es) 2016-09-23
US11648206B2 (en) 2023-05-16
US20150094322A1 (en) 2015-04-02
BR112015026418B1 (pt) 2022-10-04
ZA201507723B (en) 2023-05-31
MX2020012310A (es) 2021-01-29
EP2986280B1 (fr) 2021-03-17
EA037375B1 (ru) 2021-03-22
US20190054028A1 (en) 2019-02-21
EP2986280A2 (fr) 2016-02-24
MX377426B (es) 2025-03-10
PT2986280T (pt) 2021-05-07
MX2015014656A (es) 2016-03-01
AU2019201048A1 (en) 2019-03-07
WO2014170755A2 (fr) 2014-10-23
KR102271048B1 (ko) 2021-06-30
AU2014255434A1 (en) 2015-11-05
US20230414521A1 (en) 2023-12-28
US20200030240A1 (en) 2020-01-30
AU2019201048B2 (en) 2021-01-28
CA3255918A1 (fr) 2025-10-30
AU2020294268B2 (en) 2024-05-02
MY198452A (en) 2023-08-29
US20160081936A1 (en) 2016-03-24
CN105307643A (zh) 2016-02-03
JP2016521270A (ja) 2016-07-21

Similar Documents

Publication Publication Date Title
MA38576B2 (fr) Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
MA32568B1 (fr) Formulations pharmaceutiques contenant des ligands de recepteur de dopamine
FR2944448B1 (fr) Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
MA33219B1 (fr) Derives d'azoanthracene substitues, compositions pharmaceutiques et leurs procedes d'utilisation
MA34387B1 (fr) Compositions pharmaceutiques comprenant du lactate de 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinoline-2-one monohydraté
EP1848270A4 (fr) Administration par voie transmuqueuse de compositions medicamenteuses pour le traitement et la prevention de troubles chez les animaux
MA47301B1 (fr) Inhibiteurs sélectifs de jak1
MA28215A1 (fr) Formes galeniques de l'oxycodone à libération contrôlée pour administration orale une fois par jour
MA33023B1 (fr) Formulation d'anticorps
MX2009001711A (es) Formulaciones de liberacion sostenida de topiramato.
NO20075660L (no) Blanding for behandling av inflammatoriske sykdommer
CY1112106T1 (el) Σκευασματα παραθυρεοεiδους ορμονης και η χρηση τους
EP3616696A4 (fr) Composition pharmaceutique contenant de l'enzalutamide pouvant être administrée par voie orale
MA27710A1 (fr) Formulations pharmaceutiques liquides de palonosetrone
MA33463B1 (fr) Compositions à dose pharmaceutique solide fixe comprenant de l'irbésartan et de l'amlodipine, leur préparation et leur application thérapeutique
MA29723B1 (fr) Composes
MA32964B1 (fr) Formulation a effet retard d'octreotide avec niveau d'exposition constamment eleves
MA34670B1 (fr) Inhibiteurs de l'apoptose et leurs utilisations
MA37317A1 (fr) Formulation d'anticorps il-17
MA50201B1 (fr) Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants
PH12021550391A1 (en) Pharmaceutical composition for preventing or treating nonalcoholic fatty liver disease, containing gpr119 ligand as active ingredient
EP3801539A4 (fr) Compositoins pharmaceutiques solides d'administration par voie orale comprenant de la linagliptine
WO2008008882A3 (fr) Modulateur du récepteur des glucocorticoïdes et procédés d'utilisation
MA29145B1 (fr) Préparations pharmaceutiques pour le traitement de la cellulite
MA34106B1 (fr) Combinaison de composés organiques